Pyxis Oncology (PYXS) Income from Continuing Operations (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Income from Continuing Operations of 18389000.0 for Q4 2025, up 48.3% year-over-year from 12399581.43 in Q4 2024, and up 16.43% quarter-over-quarter from 22003000.0 in Q3 2025.
Pyxis Oncology (PYXS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Income from Continuing Operations for 6 consecutive years, with 18389000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations rose 48.3% year-over-year to 18389000.0; the TTM figure through Dec 2025 stood at 81303000.0 (up 5.25% YoY), while the FY2025 annual figure was 79621000.0, down 2.96% from the prior year.
- Income from Continuing Operations rose to 18389000.0 in Q4 2025 per PYXS's latest filing, from 22003000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5935000.0 in Q2 2021 and bottomed at 46370000.0 in Q3 2021.
- Historically, Income from Continuing Operations has averaged 26601450.0 across 5 years, with a median of 23272000.0 in 2023.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations slumped 1353.15% — and 2024, when it soared 54.22%.
- Pyxis Oncology's Income from Continuing Operations stood at 42167000.0 in 2021, then climbed by 15.9% to 35464000.0 in 2022, then jumped by 43.36% to 20088000.0 in 2023, then slumped by 77.08% to 35571000.0 in 2024, then surged by 48.3% to 18389000.0 in 2025.
- Business Quant data shows PYXS's Income from Continuing Operations at 18389000.0 in Q4 2025, 22003000.0 in Q3 2025, and 18354000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | -25.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.35 Mn |
| Dec 31, 2025 | -18.39 Mn |
| Sep 30, 2025 | -22.00 Mn |
| Jun 30, 2025 | -18.35 Mn |
| Mar 31, 2025 | -22.56 Mn |
| Dec 31, 2024 | -35.57 Mn |
| Sep 30, 2024 | -21.20 Mn |
| Jun 30, 2024 | -17.30 Mn |
| Mar 31, 2024 | -11.73 Mn |
| Dec 31, 2023 | -20.09 Mn |
| Sep 30, 2023 | -23.99 Mn |
| Jun 30, 2023 | -17.90 Mn |
| Mar 31, 2023 | -25.63 Mn |
| Dec 31, 2022 | -35.46 Mn |
| Sep 30, 2022 | -40.79 Mn |
| Jun 30, 2022 | -39.05 Mn |
| Mar 31, 2022 | -31.82 Mn |
| Dec 31, 2021 | -42.17 Mn |
| Sep 30, 2021 | -46.37 Mn |
| Jun 30, 2021 | -5.94 Mn |